UroGen Pharma Quarterly Balance Sheet
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma financial position
As of Jun 30, 2026, UroGen Pharma reported total assets of $252.6 million, up 21.0% from a year earlier against total liabilities of $385.0 million. Shareholders' equity was negative at -$132.4 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $79.1 million in cash and equivalents against $188.7 million of debt, a net debt position of $109.6 million.
The current ratio (current assets divided by current liabilities) was 3.80, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 79.13M | 109.97M | 110.75M | 90.04M | 92.90M | 104.03M | 171.99M | 124.92M | 219.97M | 131.44M | 95.00M | 119.31M |
| Short-Term Investments | 30.16M | 39.74M | 49.31M | 63.79M | 83.11M | 112.03M | 110.67M | 153.93M | 52.28M | 51.72M | 56.16M | 55.30M |
| Receivables | 88.76M | 55.41M | 33.08M | 19.70M | 19.65M | 19.64M | 20.30M | 22.80M | 17.41M | 14.16M | 15.44M | 12.85M |
| Inventory | 24.59M | 20.92M | 16.46M | 8.34M | 7.13M | 7.59M | 9.23M | 7.59M | 7.44M | 7.24M | 5.67M | 5.00M |
| Total Current Assets | 235.43M | 237.46M | 186.02M | 168.55M | 196.87M | 237.18M | 276.13M | 295.10M | 278.97M | 196.76M | 169.19M | 182.12M |
| Property, Plant & Equipment | 597.00K | 616.00K | 637.00K | 695.00K | 688.00K | 627.00K | 655.00K | 608.00K | 580.00K | 566.00K | 689.00K | 823.00K |
| Long-Term Investments | — | — | 0 | 380.00K | 4.63M | 4.51M | 5.02M | 4.64M | 203.00K | 481.00K | 4.50M | 6.51M |
| Total Assets | 252.59M | 253.69M | 200.46M | 185.05M | 208.72M | 247.62M | 285.71M | 301.94M | 281.85M | 200.57M | 178.31M | 193.63M |
| Accounts Payable | 15.47M | 17.21M | 12.14M | 10.28M | 13.56M | 14.57M | 10.93M | 5.56M | 8.32M | 6.26M | 6.51M | 4.04M |
| Total Current Liabilities | 61.91M | 50.63M | 46.42M | 42.24M | 47.55M | 42.00M | 45.95M | 32.79M | 34.22M | 26.34M | 31.21M | 25.79M |
| Long-Term Debt | 188.73M | 189.53M | 122.21M | 122.11M | 122.51M | 122.11M | 121.73M | 121.71M | 97.81M | 97.59M | 98.55M | 98.52M |
| Total Liabilities | 384.99M | 377.94M | 305.93M | 300.45M | 302.09M | 294.08M | 294.51M | 276.43M | 251.53M | 240.71M | 243.52M | 235.63M |
| Shareholders' Equity | -132.40M | -124.25M | -105.47M | -115.41M | -93.38M | -46.46M | -8.80M | 25.52M | 30.31M | -40.13M | -65.21M | -41.99M |
| Retained Earnings | -997.64M | -983.29M | -959.72M | -933.35M | -900.00M | -850.07M | -806.22M | -768.71M | -745.04M | -711.63M | -679.35M | -653.33M |
| Total Debt | 188.73M | 189.53M | 122.21M | 122.11M | 122.51M | 122.11M | 121.73M | 121.71M | 97.81M | 97.59M | 98.55M | 98.52M |
| Net Cash (Debt) | -79.44M | -39.82M | 37.84M | 31.72M | 53.51M | 93.95M | 160.93M | 157.14M | 174.44M | 85.57M | 52.61M | 76.09M |
| Shares Outstanding | 48.87M | 48.71M | 48.35M | 46.78M | 46.20M | 46.10M | 42.23M | 42.19M | 41.17M | 36.13M | 32.49M | 42.20M |
This table shows 12 quarterly periods of UroGen Pharma's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a balance sheet?